Cardiology

Ahmad Masri, MD, MS, highlights a trio of studies from ESC Congress 2024 examining use of aficamten in hypertrophic cardiomyopathy.

EMPACT-MI study shows empagliflozin is safe post-acute MI and reduces heart failure events, with kidney protection across kidney function levels.

ESC 2024: Phase 3 PALISADE trial shows plozasiran significantly lowers triglycerides and pancreatitis risk in FCS; NDA planned by year-end.

MAVA-LTE trial data show mavacamten's sustained benefits in symptomatic obstructive HCM, with long-term improvements in LVOT, NT-proBNP, and quality of life.

A meta-analysis shows GLP-1 RAs and SGLT2 inhibitors offer distinct cardiovascular and kidney benefits in type 2 diabetes.

FINEARTS-HF results suggest finerenone may join SGLT2 inhibitors as a second pillar in treating HFmrEF/HFpEF, cutting total heart failure events by 16%.

Asundexian failed to prove noninferiority to apixaban for its primary efficacy outcome in the phase 3 OCEANIC-AF trial.

RESHAPE-HF2 shows mitral transcatheter edge-to-edge repair (M-TEER) reduces heart failure hospitalizations and improves quality of life vs optimal medical therapy alone.

A single blood test using hsCRP, LDL-C, and Lp(a) levels can predict cardiovascular risk for women up to 30 years, emphasizing personalized care.

Women with endometriosis experienced a 20% greater risk of cardiac outcomes compared with women without endometriosis.

The STOP-or-NOT trial found similar outcomes for continuation or discontinuation of RAS inhibitors before noncardiac surgery, supporting individualized decision-making.

People with the most weekend catch-up sleep had a 20% lower risk of heart disease, especially those who were sleep-deprived during the week.

HELIOS-B trial shows vutrisiran reduces all-cause mortality and CV events in ATTR-CM, with benefits consistent regardless of tafamidis use.

The ABYSS trial suggests no clear benefit of continuing beta-blockers post-MI in patients with preserved LVEF, echoing REDUCE-AMI findings.

Patients with stable CAD who quit smoking reduced the risk of a major event by nearly 50%, while a reduction in smoking habits demonstrated minimal effects.

Kausik Ray, MD, discusses what trials and new data in lipidology he is most looking forward to from the upcoming ESC Congress.

Allegheny Health Network (AHN) Cardiovascular Institute is one of only a few centers offering intracoronary vascular brachytherapy, an innovative procedure providing hope for patients with challenging restenosis.

Allegheny Health Network (AHN) implants innovative device to manage central sleep apnea in heart failure patients, reducing mortality rise and improving quality of life.

A subgroup analysis of the SELECT trial confirmed semaglutide 2.4 mg benefits patients with heart failure across ejection fraction spectra, improving MACE and heart failure outcomes.

Cascade testing strategies significantly increased the detection of FH, with direct contact yielding a 16-fold higher testing rate, according to the IMPACT-FH study.

Laurence Sperling, MD, offers perspective on multiple topics within the evolving field of lipid management and dyslipidemia.

On August 19, 2024, Liquidia Corporation announced the FDA's tentative approval of treprostinil inhalation powder for adults with PAH and PH-ILD.

A recent study found that noise exposure of power looms (≥ 85 decibels) puts workers at risk of their overall blood pressure increasing.

HIIT exercise post-stroke improved aerobic fitness more than MICT, with significant gains in peak VO2 after 12 weeks.

Deepak Bhatt, MD, MPH, MBA, discusses 7 trials to watch from hotline or late-breaking sessions at the upcoming European Society of Cardiology Congress 2024.

New study suggests MRI-derived pressure measurements indicate a 5-fold increase in heart failure risk.

Laurence Sperling, MD, provides an overview of the Family Heart Global Summit, including previewing the meeting and discussing where interested attendees can learn more.

Maintaining stable HbA1c levels in target ranges reduces Alzheimer Disease risk in older adults with diabetes, emphasizing the importance of personalized glycemic control.

A new real-world study suggests tirzepatide provides greater reductions in mortality, cardiovascular risk, and kidney events than GLP-1 receptor agonists in type 2 diabetes.

On August 05, 2024, less than a month prior to its presentation at ESC 24, Bayter has announced topline data from the FINEARTS-HF trial indicating finerenone met the primary endpoint.